Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).
Belinostat
Chidamide
HDACi
Histone deacetylase
PTCL
Romidepsin
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
02 08 2023
02 08 2023
Historique:
received:
28
02
2023
accepted:
05
07
2023
medline:
4
8
2023
pubmed:
3
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
Peripheral T-cell lymphomas (PTCLs) are a group of highly aggressive malignancies with generally poor prognoses, and the first-line chemotherapy of PTCL has limited efficacy. Currently, several novel targeted agents, including histone deacetylase inhibitors (HDACis), have been investigated to improve the therapeutic outcome of PTCLs. Several HDACis, such as romidepsin, belinostat, and chidamide, have demonstrated favorable clinical efficacy and safety in PTCLs. More novel HDACis and new combination therapies are undergoing preclinical or clinical trials. Mutation analysis based on next-generation sequencing may advance our understanding of the correlation between epigenetic mutation profiles and relevant targeted therapies. Multitargeted HDACis and HDACi-based prodrugs hold promising futures and offer further directions for drug design.
Identifiants
pubmed: 37533111
doi: 10.1186/s13148-023-01531-8
pii: 10.1186/s13148-023-01531-8
pmc: PMC10398948
doi:
Substances chimiques
Histone Deacetylase Inhibitors
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
124Informations de copyright
© 2023. The Author(s).
Références
Clin Cancer Res. 2015 Sep 15;21(18):4097-109
pubmed: 25878331
Biomed Pharmacother. 2020 Nov;131:110607
pubmed: 32841898
Cell Death Dis. 2014 Oct 16;5:e1476
pubmed: 25321483
Blood. 2018 Jan 25;131(4):397-407
pubmed: 29141948
Haematologica. 2018 Jul;103(7):1191-1197
pubmed: 29599200
Leuk Lymphoma. 2019 Apr;60(4):912-919
pubmed: 30301414
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
Blood. 2021 Apr 22;137(16):2161-2170
pubmed: 33171487
Am J Hematol. 2022 May;97(5):623-629
pubmed: 35170082
Blood. 2013 Feb 21;121(8):1335-44
pubmed: 23287868
Int J Hematol. 2017 Nov;106(5):655-665
pubmed: 28664499
Hematology Am Soc Hematol Educ Program. 2011;2011:515-24
pubmed: 22160083
Ann Hematol. 2014 Mar;93(3):459-62
pubmed: 24441915
Nat Cell Biol. 2020 Sep;22(9):1064-1075
pubmed: 32839551
Cell Rep. 2022 Apr 19;39(3):110695
pubmed: 35443168
Leuk Lymphoma. 2020 Feb;61(2):309-317
pubmed: 31617432
Pharmacol Res. 2021 Jan;163:105274
pubmed: 33171304
J Biol Chem. 2013 Sep 20;288(38):27232-27242
pubmed: 23926105
Cancer Manag Res. 2015 Jun 03;7:145-51
pubmed: 26082661
Br J Haematol. 2015 Mar;168(6):811-9
pubmed: 25404094
J Clin Oncol. 2022 Jan 20;40(3):242-251
pubmed: 34843406
Lancet Haematol. 2015 Aug;2(8):e326-33
pubmed: 26688485
Cardiovasc Res. 2020 Apr 1;116(5):970-982
pubmed: 31346605
Clin Cancer Res. 2015 Oct 15;21(20):4663-75
pubmed: 26116270
Int J Biochem Cell Biol. 2017 Oct;91(Pt A):45-52
pubmed: 28864268
Angew Chem Int Ed Engl. 2020 Feb 17;59(8):3028-3032
pubmed: 31943585
Oncogene. 2017 Mar 30;36(13):1804-1815
pubmed: 27721407
Nat Rev Cancer. 2020 Jun;20(6):323-342
pubmed: 32249838
J Genet Genomics. 2022 Apr;49(4):287-298
pubmed: 34856390
Clin Cancer Res. 2015 May 1;21(9):2096-106
pubmed: 25677697
J Clin Oncol. 2012 Feb 20;30(6):631-6
pubmed: 22271479
J Hematol Oncol. 2016 Mar 10;9:22
pubmed: 26965915
Cancer Biol Med. 2021 Mar 23;:
pubmed: 33755379
Cancers (Basel). 2021 May 04;13(9):
pubmed: 34064441
FASEB J. 2022 Jul;36(7):e22326
pubmed: 35657209
J Med Chem. 2019 Apr 25;62(8):3898-3923
pubmed: 30901208
Chin J Cancer Res. 2021 Oct 31;33(5):616-626
pubmed: 34815635
J Med Chem. 2017 Oct 12;60(19):7965-7983
pubmed: 28885834
Acta Haematol. 2019;141(4):216-221
pubmed: 30943470
Front Endocrinol (Lausanne). 2022 Oct 20;13:989305
pubmed: 36339432
Mol Oncol. 2012 Dec;6(6):637-56
pubmed: 23141799
Cytokine. 2019 Jan;113:371-379
pubmed: 30327172
Br J Haematol. 2020 Jan;188(2):295-308
pubmed: 31452195
Antioxid Redox Signal. 2018 Mar 10;28(8):643-661
pubmed: 28891317
Mol Immunol. 2014 Jul;60(1):44-53
pubmed: 24747960
J Hematol Oncol. 2016 Apr 12;9:38
pubmed: 27071522
J Clin Invest. 2015 Mar 2;125(3):1111-23
pubmed: 25642770
Apoptosis. 2020 Jun;25(5-6):370-387
pubmed: 32394008
Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4179-84
pubmed: 18326024
Sci Signal. 2016 Aug 09;9(440):ra79
pubmed: 27507649
Expert Rev Hematol. 2019 Mar;12(3):137-146
pubmed: 30782038
Annu Rev Pathol. 2018 Jan 24;13:293-320
pubmed: 29414251
Nat Commun. 2017 May 18;8:15368
pubmed: 28516954
Arch Pharm Res. 2015 Jun;38(6):933-49
pubmed: 25653088
Nat Rev Mol Cell Biol. 2019 Mar;20(3):156-174
pubmed: 30467427
Cancer Res. 2021 Dec 15;81(24):6233-6245
pubmed: 34711611
Pharmacol Ther. 2021 May;221:107748
pubmed: 33245993
Exp Hematol Oncol. 2021 Feb 18;10(1):15
pubmed: 33602316
Cancer Sci. 2022 Aug;113(8):2778-2787
pubmed: 35579212
Biochem Soc Trans. 2011 Aug;39(4):1092-5
pubmed: 21787354
Oncologist. 2021 Mar;26(3):184-e366
pubmed: 33458921
Br J Haematol. 2015 Oct;171(2):215-226
pubmed: 26194163
Cell Biosci. 2022 Jun 3;12(1):81
pubmed: 35658939
Clin Cancer Res. 2015 Jun 15;21(12):2666-70
pubmed: 25802282
J Invest Dermatol. 2020 Oct;140(10):2009-2022.e4
pubmed: 32119867
Genes Cancer. 2015 May;6(5-6):184-213
pubmed: 26124919
FASEB J. 2005 Jun;19(8):966-8
pubmed: 15772115
J Biol Chem. 2009 Oct 30;284(44):30673-83
pubmed: 19736310
Histopathology. 2009 May;54(6):688-98
pubmed: 19438744
Signal Transduct Target Ther. 2021 Sep 4;6(1):333
pubmed: 34482361
Clin Cancer Res. 2014 Sep 15;20(18):4849-60
pubmed: 25070836
Sci Signal. 2022 Dec 20;15(765):eabo4356
pubmed: 36538592
Expert Opin Pharmacother. 2021 Jun;22(9):1203-1215
pubmed: 33524268
Cancers (Basel). 2020 Sep 08;12(9):
pubmed: 32911820
Clin Epigenetics. 2020 Nov 7;12(1):169
pubmed: 33160401
J Med Chem. 2019 Apr 11;62(7):3171-3183
pubmed: 30418766
Microbiol Spectr. 2023 Feb 2;:e0123722
pubmed: 36728436
Nat Rev Immunol. 2018 Oct;18(10):617-634
pubmed: 30022149
Expert Opin Drug Discov. 2017 Aug;12(8):859-873
pubmed: 28641053
Front Cell Dev Biol. 2020 Oct 09;8:577215
pubmed: 33163492
Blood. 2017 Dec 14;130(24):2619-2630
pubmed: 29084772
Cell Death Differ. 2018 Dec;25(12):2053-2070
pubmed: 29515255
Oncogene. 2021 Mar;40(10):1836-1850
pubmed: 33564072
Blood. 2017 Jul 13;130(2):146-155
pubmed: 28550044
J Clin Oncol. 2015 Aug 10;33(23):2492-9
pubmed: 26101246
Mol Cancer. 2020 Jan 7;19(1):5
pubmed: 31910827
Sci Transl Med. 2021 Apr 7;13(588):
pubmed: 33827976
Eur J Med Chem. 2021 Dec 15;226:113825
pubmed: 34562854
mSphere. 2019 Jul 10;4(4):
pubmed: 31292228
Nat Commun. 2018 Jul 16;9(1):2741
pubmed: 30013077
J Clin Invest. 2013 Jul;123(7):3112-23
pubmed: 23921131
Br J Haematol. 2013 Jul;162(1):138-41
pubmed: 23590726
EClinicalMedicine. 2022 Oct 01;54:101674
pubmed: 36204003
Cancer Biol Ther. 2016 Oct 2;17(10):1094-1106
pubmed: 27657380
J Cancer Res Clin Oncol. 2020 Dec;146(12):3123-3135
pubmed: 32995955
Haematologica. 2020 Jan;105(1):e26-e28
pubmed: 31073068
Ann Oncol. 2010 Apr;21(4):860-863
pubmed: 19887465
J Med Chem. 2021 Jun 10;64(11):7468-7482
pubmed: 34043359
J Inorg Biochem. 2020 May;206:110981
pubmed: 32088592
Leuk Lymphoma. 2017 Oct;58(10):2310-2318
pubmed: 28270022
Eur J Med Chem. 2020 Oct 1;203:112628
pubmed: 32679451
Leukemia. 2008 May;22(5):1026-34
pubmed: 18256683
Elife. 2018 Apr 17;7:
pubmed: 29664401
Clin Cancer Res. 2020 Mar 1;26(5):1000-1008
pubmed: 31772119
Sci Rep. 2020 Jan 16;10(1):424
pubmed: 31949209
Int J Cancer. 2016 Jan 1;138(1):125-36
pubmed: 26205347
Am J Hematol. 2021 Oct 1;96(10):1211-1222
pubmed: 34251048
Ann Oncol. 2015 Aug;26(8):1766-71
pubmed: 26105599